MMPs/TIMPs and inflammatory signalling de-regulation in human incisional hernia tissues

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 11-12, 2009, Pages 4432-4443

  Guillen Marti, Jordi ^a   Diaz, Ramon ^a   Quiles, Maria T ^a   Lopez Cano, Manuel ^a   Vilallonga, Ramon ^a   Huguet, Pere ^a   Ramon y Cajal, Santiago ^a   Sanchez Niubo, Albert ^b   Reventós, Jaume ^a   Armengol, Manel ^a   Arbos, Maria A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Aponeurosis; Extracellular matrix; IL 6; Incisional hernia; MMP TIMP; Skeletal muscle; TNFA; TNFRSFs

Indexed keywords

MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE;

ABDOMINAL WALL HERNIA; ADULT; AGED; ARTICLE; ENZYMOLOGY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HERNIA, ABDOMINAL; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77951146580     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00637.x     Document Type: Article

References (53)

1. Kingsnorth A, LeBlanc K. Hernias: inguinal and incisional. Lancet. 2003, 362:1561-71.
2. Flum DR, Horvath K, Koepsell T. Have outcomes of incisional hernia repair improved with time? A population-based analysis. Ann Surg. 2003, 237:129-35.
3. Klinge U, Conze J, Krones CJ. Incisional hernia: open techniques. World J Surg. 2005, 29:1066-72.
4. Yahchouchy-Chouillard E, Aura T, Picone O. Incisional hernias. I. Related risk factors. Dig Surg. 2003, 20:3-9.
5. Jansen PL, Mertens PR, Klinge U. The biology of hernia formation. Surgery. 2004, 136:1-4.
6. Franz MG. The biology of hernia formation. Surg Clin North Am. 2008, 88:1-15. vii
7. Klinge U, Si ZY, Zheng H. Collagen I/III and matrix metalloproteinases (MMP) 1 and 13 in the fascia of patients with incisional hernias. J Invest Surg. 2001, 14:47-54.
8. Si Z, Bhardwaj R, Rosch R. Impaired balance of type I and type III procollagen mRNA in cultured fibroblasts of patients with incisional hernia. Surgery. 2002, 131:324-31.
9. Salameh JR, Talbott LM, May W. Role of biomarkers in incisional hernias. Am Surg. 2007, 73:561-7.
10. Rosch R, Junge K, Knops M. Analysis of collagen-interacting proteins in patients with incisional hernias. Langenbecks Arch Surg. 2003, 387:427-32.
11. Riley G. Tendinopathy - from basic science to treatment. Nat Clin Pract Rheumatol. 2008, 4:82-9.
12. Woessner JF. MMPs and TIMPs-an historical perspective. Mol Biotechnol. 2002, 22:33-49.
13. Giannoudis PV, Dinopoulos H, Chalidis B. Surgical stress response. Injury. 2006, 37:S3-9. Suppl 5
14. Di Vita G, Patti R, D'Agostino P. Cytokines and growth factors in wound drainage fluid from patients undergoing incisional hernia repair. Wound Repair Regen. 2006, 14:259-64.
15. Schönherr E, Hausser HJ. Extracellular matrix and cytokines: a functional unit. Dev Immunol. 2000, 7:89-101.
16. Tran KT, Griffith L, Wells A. Extracellular matrix signalling through growth factor receptors during wound healing. Wound Repair Regen. 2004, 12:262-8.
17. Rath AM, Chevrel JP. The healing of laparotomies: review of the literature. Hernia. 1998, 2:145-9.
18. Demoule A, Divangahi M, Yahiaoui L. Endotoxin triggers nuclear factor-kappaB-dependent up-regulation of multiple proinflammatory genes in the diaphragm. Am J Respir Crit Care Med. 2006, 174:646-53.
19. Arbos MA, Ferrando JM, Quiles MT. Improved surgical mesh integration into the rat abdominal wall with arginine administration. Biomaterials. 2006, 27:758-68.
20. Oliver GW, Leferson JD, Stetler-Stevenson WG. Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal Biochem. 1997, 244:161-6.
21. Morrison DF. Multivariate statistical methods 1990, 3rd ed, New York, McGraw-Hill
22. Clark IM, Swingler TE, Sampieri CL. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008, 40:1362-78.
23. Celli BR, Calverley PM, Rennard SI. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med. 2005, 99:1546-54.
24. Varani J, Dame MK, Rittie L. Decreased collagen production in chronologically aged skin: roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am J Pathol. 2006, 168:1861-8.
25. Fligiel SE, Varani J, Datta SC. Collagen degradation in aged/photodamaged skin in vivo and after exposure to matrix metalloproteinase-1 in vitro. J Invest Dermatol. 2003, 120:842-8.
26. Pischon N, Darbois LM, Palamakumbura AH. Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts. J Biol Chem. 2004, 279:30060-5.
27. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003, 200:448-64.
28. Han YP, Nien YD, Garner WL. Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase. J Biol Chem. 2002, 277:27319-27.
29. Sørensen LT. Effect of lifestyle, gender and age on collagen formation and degradation. Hernia. 2006, 10:456-61.
30. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002, 3:207-14.
31. Masumoto K, de Rooij JD, Suita S. The distribution of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the lungs of congenital diaphragmatic hernia patients and age-matched controls. Histopathology. 2006, 48:588-95.
32. Radisky DC, Levy DD, Littlepage LE. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005, 436:123-7.
33. Mirastschijski U, Impola U, Jahkola T. Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds. Hum Pathol. 2002, 33:355-64.
34. St-Pierre Y, Van Themsche C, Estève PO. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy. 2003, 2:206-15.
35. Tran KT, Lamb P, Deng JS. Matrikines and matricryptins: implications for cutaneous cancers and skin repair. J Dermatol Sci. 2005, 40:11-20.
36. Opdenakker G, Dillen C, Fiten P. Remnant epitopes, autoimmunity and glycosylation. Biochim Biophys Acta. 2006, 1760:610-5.
37. Abci I, Bilgi S, Altan A. Role of TIMP-2 in fascia transversalis on development of inguinal hernias. J Invest Surg. 2005, 18:123-8.
38. Woessner JF. That impish TIMP: the tissue inhibitor of metalloproteinases-3. J Clin Invest. 2001, 108:799-800.
39. Amour A, Slocombe PM, Webster A. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998, 435:39-44.
40. Black RA. TIMP3 checks inflammation. Nat Genet. 2004, 36:934-5.
41. Leco KJ, Waterhouse P, Sanchez OH. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest. 2001, 108:817-29.
42. Fedak PW, Smookler DS, Kassiri Z. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation. 2004, 110:2401-9.
43. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006, 444:860-7.
44. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1997, 10:411-52.
45. MacEwan DJ. TNF ligands and receptors-a matter of life and death. Br J Pharmacol. 2002, 135:855-75.
46. Theiss AL, Simmons JG, Jobin C. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005, 280:36099-109.
47. Porteu F, Hieblot C. Tumour necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem. 1994, 269:2834-40.
48. Higuchi Y, McTiernan CF, Frye CB. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation. 2004, 109:1892-7.
49. Zhan M, Jin B, Chen SE. TACE release of TNF-alpha mediates mechanostransduction induced activation of p38 MAPK and myogenesis. J Cell Sci. 2006, 120:692-701.
50. Chen S, Jin B, Li YP. TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol. 2007, 292:C1660-71.
51. Kern PA, Ranganathan S, Li C. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-51.
52. Tsujinaka T, Fujita J, Ebisui C. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996, 97:244-9.
53. Fisher GJ, Varani J, Voorhees JJ. Looking older: fibroblast collapse and therapeutic implications. Arch Dermatol. 2008, 144:666-72.